Intervention not reported
Fingolimod (Direct evidence; 2 RCTs; 2355 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
The intervention showed no clear difference in fingolimod (Direct evidence; 2 RCTs; 2355 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Glatiramer acetate (Direct evidence; 3 RCTs; 2371 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
The intervention showed no clear difference in glatiramer acetate (Direct evidence; 3 RCTs; 2371 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Interferon beta‐1b (Betaferon) No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
The intervention showed no clear difference in interferon beta‐1b (Betaferon) No direct evidence (moderate certainty).
1 finding from 1 review
OR 0.92 [0.55, 1.54]
1 participants
Moderate
Intervention not reported
Interferon beta‐1a (Rebif, Avonex) (Direct evidence; 1 RCT; 897 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
It is very uncertain whether the intervention changes interferon beta‐1a (Rebif, Avonex) (Direct evidence; 1 RCT; 897… (very low certainty).
1 finding from 1 review
Intervention not reported
Laquinimod (Direct evidence; 3 RCTs; 3457 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
It is very uncertain whether the intervention changes laquinimod (Direct evidence; 3 RCTs; 3457 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
It is very uncertain whether the intervention changes pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512… (very low certainty).
1 finding from 1 review
Intervention not reported
Mitoxantrone (Direct evidence; 1 RCT; 53 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
It is very uncertain whether the intervention changes mitoxantrone (Direct evidence; 1 RCT; 53 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Natalizumab (Direct evidence; 1 RCT; 939 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
The intervention showed no clear difference in natalizumab (Direct evidence; 1 RCT; 939 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Ocrelizumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
It is very uncertain whether the intervention changes ocrelizumab No direct evidence (very low certainty).
1 finding from 1 review
OR 1 [0.58, 1.72]
Studies not reported
Very low
Intervention not reported
Interferon beta‐1a (Avonex, Rebif) (Direct evidence; 1 RCT; 560 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention may leads to lower interferon beta‐1a (Avonex, Rebif) (Direct evidence; 1 RCT; 560… (low certainty).
1 finding from 1 review
Intervention not reported
Ofatumumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
It is very uncertain whether the intervention changes ofatumumab No direct evidence (very low certainty).
1 finding from 1 review
OR 1.52 [0.89, 2.57]
Studies not reported
Very low
Intervention not reported
Ozanimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
It is very uncertain whether the intervention changes ozanimod No direct evidence (very low certainty).
1 finding from 1 review
OR 1.5 [0.85, 2.64]
Studies not reported
Very low
Intervention not reported
Ponesimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
It is very uncertain whether the intervention changes ponesimod No direct evidence (very low certainty).
1 finding from 1 review
OR 1.24 [0.66, 2.35]
Studies not reported
Very low
Intervention not reported
Teriflunomide (Direct evidence; 2 RCTs; 2253 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
It is very uncertain whether the intervention changes teriflunomide (Direct evidence; 2 RCTs; 2253 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Placebo · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Spasticity: number of participants reporting reduction of 30% in the spasticity NRS ( · health problem or population
Summary of findings table ‐ Cannabis probably leads to higher spasticity: number of participants reporting reduction of 30% in the… compared with placebo (moderate certainty).
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · health problem or population
It is very uncertain whether summary of findings table ‐ Cannabis changes pain:number of participants reporting pain relief of 50% or greater… compared with placebo (very low certainty).
1 finding from 1 review
Patient Global Impression of Change much or very much improved · health problem or population
Summary of findings table ‐ Cannabis probably leads to higher PGIC:number of participants reporting much or very much improvement… compared with placebo (moderate certainty).
1 finding from 1 review
Health‐related quality of life. Mean change from baseline · health problem or population
1 finding from 1 review
Number withdrawn due to adverse events · health problem or population
Summary of findings table ‐ Cannabis may leads to higher withdrawn due to adverse events ( compared with placebo (low certainty).
1 finding from 1 review